Claims

1. Use of aticaprant, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of major depressive disorder in a human patient having anhedonia, wherein an effective amount of the medicament is to be administered to the human patient.

2. The use of claim 1, wherein the patient had an inadequate response to other antidepressant therapy prior to treatment with the aticaprant.

3. The use of claim 2, wherein the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

4. The use of any preceding claim, wherein the aticaprant, or the pharmaceutically acceptable salt thereof, is formulated to be administered in an adjunctive treatment with an effective amount of one or more antidepressants.

5. The use of claim 4, wherein the one or more antidepressants is a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

6. The use of any preceding claim, wherein the aticaprant is S-aticaprant, or a pharmaceutically acceptable salt thereof.

7. The use of any preceding claim, wherein the effective amount of the aticaprant is 2 to 35 mg.

8. The use of any preceding claim, wherein the effective amount of the aticaprant is 10 mg.

9. The use of any preceding claim, wherein the aticaprant is to be administered orally.

10. The use of any preceding claim, wherein the aticaprant is to be administered once daily.

11. The use of any preceding claim, wherein the patient has a Snaith Hamilton Pleasure Scale (SHAPS) score of 20 or greater.

12. The use of any preceding claim, wherein the patient has a SHAPS score of 22 or greater, 24 or greater, 26 or greater, 28 or greater, 30 or greater, 32 or greater, 34 or greater, 36 or greater, or 38 or greater.

13. The use of any preceding claim, wherein the patient has a SHAPS score of 38 or greater.

14. The use of any preceding claim, wherein the patient has moderate or severe anhedonia.

15. The use of claim 14, wherein the patient has moderate anhedonia.

16. The use of claim 14, wherein the patient has severe anhedonia.

17. The use of any preceding claim, wherein the patient does not experience weight gain during the treatment with the aticaprant.

18. The use of claim 17, wherein patient's body weight is assessed at the initial time the aticaprant is to be administered.

19. The use of any preceding claim, wherein the patient does not experience a decrease in sexual functioning during the treatment with the aticaprant.

20. The use of claim 19, wherein the sexual functioning of the patient is assessed at the initial time the aticaprant is to be administered.

21. The use of claim 19 or claim 20, wherein the sexual functioning comprises sexual drive, sexual arousal, vaginal lubrication, erection, orgasm achievement, or orgasm satisfaction.

22. The use of any of claims 19 to 21, wherein sexual functioning is assessed by the Arizona Sexual Experience Scale (ASEX).

23. The use of any preceding claim, wherein the anhedonia of the patient is reduced by at least 40%, as measured by the change from baseline in total score in an anhedonia scale following 6 weeks of the treatment with the aticaprant.

24. The use of any preceding claim, wherein the anhedonia of the patient is reduced within 3 weeks to 6 weeks as measured by the change from baseline in total score in an anhedonia scale.

25. The use of claim 23 or claim 24, wherein the anhedonia scale is the Snaith Hamilton Pleasure Scale (SHAPS).

26. The use of any preceding claim, wherein, after the time the aticaprant is to be administered, the aticaprant achieves a maximum plasma concentration (C_{max}) of aticaprant of 20 to 45 ng/mL.

27. The use of any preceding claim, wherein, after the time the aticaprant is to be administered, the aticaprant achieves a maximum plasma concentration (C_{max}) of aticaprant of 25 to 35 ng/mL.

28. The use of any preceding claim, wherein, after the time the aticaprant is to be administered, the aticaprant achieves a maximum plasma concentration (C_{max}) of aticaprant of 30 to 35 ng/mL.

29. Aticaprant, or a pharmaceutically acceptable salt thereof, for use in treatment of major depressive disorder in a human patient.

30. Use of aticaprant or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment of major depressive disorder in a human patient, wherein an effective amount of the medicament is to be administered to the human patient.

31. The use of claim 30, wherein the patient had an inadequate response to other antidepressant therapy prior to treatment with the aticaprant.

32. The use of claim 31, wherein the other antidepressant therapy comprised a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

33. The use of any of claims 30-32, wherein the aticaprant,or the pharmaceutically acceptable salt thereof, is formulated to be administered in an adjunctive treatment with an effective amount of one or more antidepressants.

34. The use of claim 33, wherein the one or more antidepressants is a selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or a combination thereof.

35. The use of any of claims 30-34, wherein the aticaprant is S-aticaprant, or a pharmaceutically acceptable salt thereof.

36. The use of any of claims 30-35, wherein the aticaprant or the pharmaceutically acceptable salt thereof is formulated to be administered in an amount of 2 to 35 mg.

37. The use of any of claims 30-36, wherein the aticaprant or the pharmaceutically acceptable salt thereof is formulated to be administered in an amount of 10 mg.

38. The use of any of claims 30-37, wherein the aticaprant or the pharmaceutically acceptable salt thereof is formulated to be administered orally.

39. The use of any of claims 30-38, wherein the aticaprant or the pharmaceutically acceptable salt thereof is formulated to be administered once daily.

40. The use of any of claims 30-39, wherein the patient has a Snaith Hamilton Pleasure Scale (SHAPS) score of 20 or greater.

41. The use of any of claims 30-40, wherein the patient has a SHAPS score of 22 or greater, 24 or greater, 26 or greater, 28 or greater, 30 or greater, 32 or greater, 34 or greater, 36 or greater, or 38 or greater.

42. The use of any of claims 30-41, wherein the patient has a SHAPS score of 38 or greater.

43. The use of any of claims 30-42, wherein the patient does not experience weight gain during the treatment with the aticaprant or the pharmaceutically acceptable salt thereof.

44. The use of claim 43, wherein patient's body weight is assessed at the initial time the aticaprant, or the pharmaceutically acceptable salt thereof, is to be administered.

45. The use of any of claims 30-44, wherein the patient does not experience a decrease in sexual functioning during the treatment with the aticaprant or the pharmaceutically acceptable salt thereof.

46. The use of claim 45, wherein the sexual functioning of the patient is assessed at the initial time the aticaprant, or the pharmaceutically acceptable salt thereof, is to be administered.

47. The use of claims 45 or 46, wherein the sexual functioning comprises sexual drive, sexual arousal, vaginal lubrication, erection, orgasm achievement, or orgasm satisfaction.

48. The use of claims 45-47, wherein sexual functioning is assessed by the Arizona Sexual Experience Scale (ASEX).

49. The use of claims 30-48, wherein the aticaprant or the pharmaceutically acceptable salt thereof achieves a maximum plasma concentration (C_{max}) of aticaprant of 20 to 45 ng/mL.

50. The use of claims 30-49, wherein the aticaprant or the pharmaceutically acceptable salt thereof achieves a maximum plasma concentration (C_{max}) of aticaprant of 25 to 35 ng/mL.

51. The use of claims 30-50, wherein the aticaprant or the pharmaceutically acceptable salt thereof achieves a maximum plasma concentration (C_{max}) of aticaprant of 30 to 35 ng/mL.